| A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT02537613) | Dana-Farber Cancer Institute | 2015-12-01 |
| Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (NCT02441686) | Dana-Farber Cancer Institute | 2015-12-01 |
| CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors (NCT02756390) | Dana-Farber Cancer Institute | 2015-12-01 |
| Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck (NCT02474368) | Dana-Farber Cancer Institute | 2015-11-01 |
| Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia (NCT02439138) | Dana-Farber Cancer Institute | 2015-10-01 |
| MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma (NCT02514824) | Dana-Farber Cancer Institute | 2015-10-01 |
| The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study (NCT02520713) | Dana-Farber Cancer Institute | 2015-10-01 |
| The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy (NCT02489617) | Dana-Farber Cancer Institute | 2015-09-01 |
| Lenalidomide for Adult Histiocyte Disorders (NCT02523040) | Dana-Farber Cancer Institute | 2015-08-01 |
| Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors (NCT02452710) | Dana-Farber Cancer Institute | 2015-08-01 |
| Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma (NCT02478164) | Dana-Farber Cancer Institute | 2015-07-13 |
| A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer (NCT02448771) | Dana-Farber Cancer Institute | 2015-07-09 |
| Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning (NCT02470910) | Dana-Farber Cancer Institute | 2015-07-01 |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer (NCT02244463) | Dana-Farber Cancer Institute | 2015-07-01 |
| Improving Informed Consent for Palliative Chemotherapy (NCT02282722) | Dana-Farber Cancer Institute | 2015-06-10 |
| A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS) (NCT02502695) | Dana-Farber Cancer Institute | 2015-06-01 |
| Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy (NCT01894451) | Dana-Farber Cancer Institute | 2015-06-01 |
| Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM (NCT02375555) | Dana-Farber Cancer Institute | 2015-05-07 |
| Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis (NCT02441140) | Dana-Farber Cancer Institute | 2015-05-01 |
| Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer (NCT02423148) | Dana-Farber Cancer Institute | 2015-05-01 |
| Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture (NCT02355340) | Dana-Farber Cancer Institute | 2015-05-01 |
| Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders (NCT02425904) | Dana-Farber Cancer Institute | 2015-05-01 |
| Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets (NCT02406521) | Dana-Farber Cancer Institute | 2015-04-01 |
| Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia (NCT02400437) | Dana-Farber Cancer Institute | 2015-04-01 |
| Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL (NCT02362997) | Dana-Farber Cancer Institute | 2015-04-01 |
| Pembrolizumab +/- Bevacizumab for Recurrent GBM (NCT02337491) | Dana-Farber Cancer Institute | 2015-02-09 |
| Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD (NCT02318082) | Dana-Farber Cancer Institute | 2015-02-01 |
| Patient-Centered Care for the Older Adult With Hematologic Malignancy (NCT02359838) | Dana-Farber Cancer Institute | 2015-02-01 |
| Image-guided Cryoablation of Head, Neck and Spine Tumors (NCT02085941) | Dana-Farber Cancer Institute | 2015-02-01 |
| A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (NCT02340676) | Dana-Farber Cancer Institute | 2015-02-01 |
| Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy (NCT02335671) | Dana-Farber Cancer Institute | 2015-02-01 |
| Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD (NCT02176031) | Dana-Farber Cancer Institute | 2015-01-01 |
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974) | Dana-Farber Cancer Institute | 2015-01-01 |
| E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma (NCT02279394) | Dana-Farber Cancer Institute | 2014-12-11 |
| A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma (NCT02086175) | Dana-Farber Cancer Institute | 2014-12-01 |
| A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL (NCT02268851) | Dana-Farber Cancer Institute | 2014-11-01 |
| Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (NCT02287428) | Dana-Farber Cancer Institute | 2014-11-01 |
| Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention (NCT02287519) | Dana-Farber Cancer Institute | 2014-11-01 |
| Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases (NCT02260531) | Dana-Farber Cancer Institute | 2014-11-01 |
| Impact of Cerebellar Mass Resection on Pain Processing (NCT02261649) | Dana-Farber Cancer Institute | 2014-10-01 |
| A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (NCT02251548) | Dana-Farber Cancer Institute | 2014-10-01 |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate (NCT02268175) | Dana-Farber Cancer Institute | 2014-10-01 |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck (NCT02113878) | Dana-Farber Cancer Institute | 2014-09-29 |
| Everolimus for Cancer With TSC1 or TSC2 Mutation (NCT02201212) | Dana-Farber Cancer Institute | 2014-09-01 |
| Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (NCT02207504) | Dana-Farber Cancer Institute | 2014-08-01 |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome (NCT02269592) | Dana-Farber Cancer Institute | 2014-08-01 |
| Personal Web Page In Clinical Trial Participant Education (NCT03887091) | Dana-Farber Cancer Institute | 2014-07-21 |
| Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases (NCT02172651) | Dana-Farber Cancer Institute | 2014-07-14 |
| A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care (NCT02279004) | Dana-Farber Cancer Institute | 2014-07-03 |
| An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease (NCT02123966) | Dana-Farber Cancer Institute | 2014-07-01 |
| Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization (NCT02118987) | Dana-Farber Cancer Institute | 2014-07-01 |
| Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST (NCT02164240) | Dana-Farber Cancer Institute | 2014-07-01 |
| A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL (NCT02158091) | Dana-Farber Cancer Institute | 2014-06-27 |
| A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (NCT02135133) | Dana-Farber Cancer Institute | 2014-06-01 |
| A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients (NCT02129686) | Dana-Farber Cancer Institute | 2014-06-01 |
| Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer (NCT02137252) | Dana-Farber Cancer Institute | 2014-05-01 |
| Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients (NCT02119897) | Dana-Farber Cancer Institute | 2014-04-01 |
| Cisplatin vs Paclitaxel for Triple Negative Breast Cancer (NCT01982448) | Dana-Farber Cancer Institute | 2014-04-01 |
| Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML (NCT02091245) | Dana-Farber Cancer Institute | 2014-03-01 |
| Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca (NCT02041429) | Dana-Farber Cancer Institute | 2014-02-01 |
| Enzalutamide + External Beam Rt For Prostate (NCT02028988) | Dana-Farber Cancer Institute | 2014-02-01 |
| Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma (NCT02036476) | Dana-Farber Cancer Institute | 2014-02-01 |
| Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer (NCT02025010) | Dana-Farber Cancer Institute | 2014-01-27 |
| Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (NCT02040857) | Dana-Farber Cancer Institute | 2014-01-01 |
| PET/CT-Assessment of Liver Tumor Ablation (NCT02018107) | Dana-Farber Cancer Institute | 2014-01-01 |
| PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors (NCT02022982) | Dana-Farber Cancer Institute | 2014-01-01 |
| Early Changes In Multiparametric MRI In Prostate Cancer (NCT01959542) | Dana-Farber Cancer Institute | 2013-12-01 |
| Healthy Living After Cancer: Weight Management Pilot Study (NCT01978899) | Dana-Farber Cancer Institute | 2013-11-01 |
| Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease (NCT01937468) | Dana-Farber Cancer Institute | 2013-11-01 |
| Tivozanib As Maintenance Therapy In GYN (NCT01972516) | Dana-Farber Cancer Institute | 2013-11-01 |
| A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma (NCT01965353) | Dana-Farber Cancer Institute | 2013-10-01 |
| Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma (NCT01955395) | Dana-Farber Cancer Institute | 2013-10-01 |
| GSK1120212+GSK2141795 for Cervical Cancer (NCT01958112) | Dana-Farber Cancer Institute | 2013-10-01 |
| Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer (NCT01942837) | Dana-Farber Cancer Institute | 2013-09-13 |
| Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (NCT01912963) | Dana-Farber Cancer Institute | 2013-09-01 |
| A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer (NCT01858688) | Dana-Farber Cancer Institute | 2013-09-01 |
| ARRY-380 + Trastuzuamab for Breast w/ Brain Mets (NCT01921335) | Dana-Farber Cancer Institute | 2013-08-01 |
| Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks (NCT01844999) | Dana-Farber Cancer Institute | 2013-08-01 |
| Impact of Radiation Therapy on Breast Conservation in DCIS (NCT02248662) | Dana-Farber Cancer Institute | 2013-08-01 |
| Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (NCT01796197) | Dana-Farber Cancer Institute | 2013-08-01 |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (NCT01746173) | Dana-Farber Cancer Institute | 2013-07-01 |
| A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01878708) | Dana-Farber Cancer Institute | 2013-07-01 |
| A Phase II Trial of Regadenoson in Sickle Cell Anemia (NCT01788631) | Dana-Farber Cancer Institute | 2013-07-01 |
| NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer (NCT01808417) | Dana-Farber Cancer Institute | 2013-06-21 |
| Tivozanib + Gemcitabine in Metastatic RCC (NCT01834183) | Dana-Farber Cancer Institute | 2013-06-01 |
| Dendritic Cell Activating Scaffold in Melanoma (NCT01753089) | Dana-Farber Cancer Institute | 2013-06-01 |
| Parental Decision-Making for Children With Relapsed Neuroblastoma (NCT02282735) | Dana-Farber Cancer Institute | 2013-05-01 |
| Sunitinib in Never-Smokers With Lung Adenocarcinoma (NCT01829217) | Dana-Farber Cancer Institute | 2013-05-01 |
| Eribulin in HER2 Negative Metastatic BrCa (NCT01827787) | Dana-Farber Cancer Institute | 2013-05-01 |
| T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) (NCT01853748) | Dana-Farber Cancer Institute | 2013-05-01 |
| Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors (NCT01782443) | Dana-Farber Cancer Institute | 2013-02-13 |
| Cabozantinib for Metastatic Triple Negative BrCa (NCT01738438) | Dana-Farber Cancer Institute | 2013-02-01 |
| Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer (NCT01783587) | Dana-Farber Cancer Institute | 2013-02-01 |
| GVAX vs. Placebo for MDS/AML After Allo HSCT (NCT01773395) | Dana-Farber Cancer Institute | 2013-01-08 |
| FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer (NCT01747551) | Dana-Farber Cancer Institute | 2013-01-01 |
| Ponatinib for Squamous Cell Lung and Head and Neck Cancers (NCT01761747) | Dana-Farber Cancer Institute | 2013-01-01 |
| Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant (NCT01754389) | Dana-Farber Cancer Institute | 2013-01-01 |
| INHERIT EGFR - Studying Germline EGFR Mutations (NCT01754025) | Dana-Farber Cancer Institute | 2012-12-28 |
| BKM120+Abiraterone Acetate for Metastatic CRPC (NCT01741753) | Dana-Farber Cancer Institute | 2012-11-01 |
| Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) (NCT01799135) | Dana-Farber Cancer Institute | 2012-11-01 |